Latest news with #clinicalinnovation
Yahoo
09-07-2025
- Business
- Yahoo
Neuronetics Showcases NeuroStar TMS Data at Clinical TMS Meeting
Neuronetics Inc. (NASDAQ:STIM) is one of the best-performing NASDAQ stocks according to analysts. On June 10, Neuronetics announced its significant presence at the 13th Annual Clinical TMS Society/CTMSS Meeting and provided an update on Greenbrook's Personalized Care Trial Program. NeuroStar, which is Neuronetics' brand, participated as a Silver Sponsor at the CTMSS Meeting, which took place from June 11 to June 14 this year in San Diego, CA. The company showcased its commitment to clinical innovation by presenting two posters derived from the TrakStar data set, which is the largest real-world outcomes database in Transcranial Magnetic Stimulation/TMS. During the CTMSS Meeting, NeuroStar presented two key data sets. One presentation focused on the largest-to-date analysis of elderly adults (age 70 and older) with Major Depressive Disorder/MDD treated with TMS. The other one provided a retrospective analysis of data from 200 Greenbrook centers, offering a direct comparison of clinical outcomes between NeuroStar's proprietary Figure-8 coil and Brainsway's H-coil in the treatment of depression. A lab technician gazing into a microscope, analyzing sample slides for medical technology research. NeuroStar also participated in the PULSES Course, a foundational training session for TMS providers, and exhibited at booth #303. Additionally, Neuronetics provided an update on Greenbrook Mental Wellness Centers' Personalized Care Trial Program. Greenbrook is a wholly-owned subsidiary of Neuronetics and initiated this program to assess the feasibility of using personalized qEEG-informed protocols for delivering TMS therapy with the NeuroStar TMS System. Neuronetics Inc. (NASDAQ:STIM) provides office treatments for patients with neurohealth disorders in the US and internationally. While we acknowledge the potential of STIM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
24-06-2025
- Business
- Yahoo
Pager Health(SM) Appoints Nationally Recognized Clinician to Lead Medical Strategy and Innovation
NEW YORK, June 24, 2025 /PRNewswire/ -- Pager Health, a connected health company that enables people to engage, navigate and access the right care in the right place at the right time, today announced the appointment of clinician, operator and innovator Dr. Ken Yamaguchi as Chief Medical Officer. Dr. Yamaguchi will help bring clinical leadership, expertise and guidance to Pager Health's product strategy, business development and care operations. "Dr. Yamaguchi brings more than 30 years of leadership at the intersection of clinical care, health system strategy, and medical innovation." said Walter Jin, Chairman and CEO of Pager Health. "He played a pivotal role at Centene, helping scale the company by over $100 billion in revenue while overseeing approximately 1,000 personnel and indirectly guiding several thousand medical and affiliated staff. He now brings his cross-disciplinary background to Pager Health, where he will drive clinical innovation, deepen medical partnerships, and ensure the company's solutions deliver measurable, real-world impact." Dr. Yamaguchi is Professor of Orthopedic Surgery at Northwestern University Feinberg School of Medicine and previously served on Centene's executive team (2015–2022), overseeing medical strategy during a period of rapid growth. Before that, he was the Sam and Marilyn Fox Distinguished Professor at Washington University and team physician for the St. Louis Cardinals. He holds a BA and MS from UCLA and an MBA from Washington University's Olin School of Business. Dr. Yamaguchi has authored over 200 publications, delivered more than 70 visiting professorships at leading institutions including Johns Hopkins, Harvard, Penn, Brown, Dartmouth, Peking University, and Oxford, and is co-founder of Protera Health, a digital MSK provider. He has also served on the executive committees of the American Orthopedic Association and American Shoulder and Elbow Surgeons, as deputy editor for the Journal of Bone and Joint Surgery, and on the board of directors of the American Academy of Orthopedic Surgeons. For more information about Pager Health, please visit About Pager HealthPager Health is a connected health platform company that enables healthcare enterprises to deliver high-engagement, intelligent health experiences across wellness, care navigation, and care management engagement. Through integrated technology, AI, and concierge services, our platform helps patients and members get the right care at the right time in the right place and stay healthy. By reducing system friction and fragmentation, powering engagement, and orchestrating the enterprise, Pager Health drives better outcomes at scale. We partner with leading payers, providers, and employers, representing more than 26 million individuals across the United States and Latin America. Media ContactPager HealthChristopher Galechris@ View original content: SOURCE Pager Health
Zawya
12-05-2025
- Business
- Zawya
AV Laboratories appoints Roula Youssef Halabi to Business Advisory Board
NEW YORK--(BUSINESS WIRE/AETOSWire)-- AV Laboratories, a leader in science-backed skincare and luxury skin longevity, proudly announces the appointment of Roula Youssef Halabi to its Business Advisory Board. With her deep expertise in healthcare, life sciences, and strategic leadership across the Middle East, Roula will play a key role in advancing AV Laboratories' mission and expanding its presence in the UAE and across the region. Roula brings over two decades of leadership in specialized medical fields, including her current role as Senior Vice President at CooperSurgical. Beyond her corporate leadership, she also serves on the board of Mecomed, a regional medical technology trade association, where she advocates for patient access, ethical practices, and regulatory advancement. 'What drew me to AV Laboratories is the brand's unwavering commitment to science-backed skincare and its vision for skin longevity,' said Roula Youssef Halabi. 'Today's consumers especially in markets like Dubai—are looking for advanced, clinical innovations that deliver real cosmetic results. They want clinically proven, proactive approaches to the visible signs of aging that mirror the scientific rigor and standards we see in clinical and personalized medicine. AVL is uniquely positioned at the forefront of this movement, and I'm thrilled to be part of its journey.' AV Laboratories is internationally recognized for its fusion of luxury and longevity. Backed by over 25 years of stem cell science, the brand offers a streamlined range of high-performance products designed to be both simple to use and clinically effective. The company is rapidly gaining traction across global markets, with the UAE seen as a high-growth region where demand for premium, evidence-based skincare is surging. 'Roula's experience and insight into the wellness ecosystem, paired with her leadership in innovation and market development, make her an invaluable addition to our advisory board,' said Ami Mezezi, CEO and Co-Founder of AV Laboratories. 'Her strategic perspective on wellness, women's health, and longevity aligns perfectly with our mission. We are especially excited about her ability to guide our expansion in the UAE and greater Middle East.' Fluent in English, French, and Arabic, and holding dual Lebanese and American nationalities, Roula brings a multicultural lens and deep market fluency to her role. Her background as a trained midwife reflects a lifelong dedication to women's health, innovation, and science-based solutions. Her appointment marks a significant step in AV Laboratories' global growth strategy as the company continues to shape the future of skincare through innovation, biotechnology, and a longevity-first philosophy. For more information, visit or follow @avllaboratories on Instagram. About AV Laboratories AV Laboratories (AVL) is a luxury longevity skincare brand pioneering science-backed innovations in molecular skincare. Inspired by over 25 years of stem cell science, AVL's patented AVL SOM3® technology empowers the skin to renew, restore, and rejuvenate, for healthy-looking, radiant skin at every age. The brand merges cutting-edge biotechnology with indulgent skincare rituals, delivering clinically proven, high-performance formulas for skin longevity. View source version on *Source: AETOSWire Contacts Media: ICR for AV Laboratories AVL@
